Journals / MN Kardiyoloji / 2003 / Cilt: 10 - Sayı: 4

Yüksek kardiyovaküler riskli hastalarda angiotensin-konverting enzim inhibitörleri: Büyük klinik çalışmalar ve meta analiz sonuçları

Angiotensin-converting enzyme inhibitors in subjects at high cardiovascular risk: Evidence from large clinical trials and meta-analyses

Pages
328–336
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

For many patients, cheaper alternatives should be considered first-line.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Angiotensin-converting enzyme inhibitors (ACE-I) currently occupy a pre-eminent position among drug classes for Cardiovascular disease.
📊
Key Findings & Data:This review compares the size of the treatment effect of ACE-I with other drug classes in subjects at high-risk of Cardiovascular events, by calculating number needed to treat for öne year (NNT-1y) to prevent Cardiovascular end-points. in patients after acute myocardial infarction (AMI), it is reasonable to restrict the use of ACE-I to those with poor left ventricular function, because the treatment benefit in other groups is small. in heart failure, ACE-I provide symptomatic benefit, but their effect on mortality is modest unless left ventricular function is especially poor. in hypertension and type-2 diabetes mellitus there are no additional benefits of ACE-I over diuretics ör (3-blockers in the prevention of death, stroke, AMI ör heart failure. in summary, in most patients at high Cardiovascular risk, ACE-I have a small treatment effect that is explained by their vasodilator and hypotensive effect.
💡
Conclusion & Impact:For many patients, cheaper alternatives should be considered first-line.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Anjiyotensin dönüştürücü enzim inhibitörleri · Kalp damar hastalıkları · Diabetes mellitus

Abstract

Angiotensin-converting enzyme inhibitors (ACE-I) currently occupy a pre-eminent position among drug classes for Cardiovascular disease. Hovvever, vvhether this therapeutic alternative should be recommended as first-line agent for subjects at high-risk of Cardiovascular events is under debate. This review compares the size of the treatment effect of ACE-I with other drug classes in subjects at high-risk of Cardiovascular events, by calculating number needed to treat for öne year (NNT-1y) to prevent Cardiovascular end-points. in patients after acute myocardial infarction (AMI), it is reasonable to restrict the use of ACE-I to those with poor left ventricular function, because the treatment benefit in other groups is small. in heart failure, ACE-I provide symptomatic benefit, but their effect on mortality is modest unless left ventricular function is especially poor. in hypertension and type-2 diabetes mellitus there are no additional benefits of ACE-I over diuretics ör (3-blockers in the prevention of death, stroke, AMI ör heart failure. in summary, in most patients at high Cardiovascular risk, ACE-I have a small treatment effect that is explained by their vasodilator and hypotensive effect. For many patients, cheaper alternatives should be considered first-line.

Özet

Angiotensin Konverting Enzim İnhibitörleri (ACEİ), zamanımızda Kardiovasküler hastalıklarda kullanılan ilaçlar arasında en önemli yeri tutmaktadırlar. Ancak bu ilaçların yüksek riskli hastalarda birinci ilaç olarak kullanılıp kullanılmayacağı tartışmalıdır. Bu derlemede, kardiyovasküler olaylar bakımından yüksek riskli hastalarda ACE inhibitörlerini diğer ilaçlarla tedavi etkinliğinin karşılaştırılması, kardiyovasküler son noktaların önlenmesi bakımından 1 yılda tedavi edilmesi gereken hasta sayısına bakılarak yapılmıştır. Miyokard infaktüslü hastalarda ACE inhibitörlerinin kullanımı sol ventrikül fonksiyonu bozuk olan hastalarla sınırlandırılmalıdır, çünkü diğer gruplarda tedavinin etkinliği çok azdır. Kalp yetmezliğinde, ACE İnhibitörleri sol ventrikül fonksiyonu özellikle çok kötü olmadığı zaman semptomatik fayda sağlar, mortalite üzerindeki etkisi ise orta derecededir. Hipertansiyon ve Tip 2 Diabetes Mellituslu hastalarda ise ölüm, stroke, akut miyokard infarktüsü veya kalp yetmezliğinin önlenmesinde ACE inhibitörlerini diüretik veya (3-blokerlara ilave bir faydası yoktur. Özet olarak yüksek kardiyovasküler riskli birçok hastada, ACE İnhibitörleri vazodilatör ve hipotansif etkileri ile küçük bir tedavi etkinliği sağlar. Birçok hasta için ilk olarak daha ucuz ilaçlar düşünülmelidir.

🔖

Cite This Article

CASAS, J., COLLISON, K., MACALLISTER, R. .. (2003). Yüksek kardiyovaküler riskli hastalarda angiotensin-konverting enzim inhibitörleri: Büyük klinik çalışmalar ve meta analiz sonuçları. MN Kardiyoloji, Cilt: 10 - Sayı: 4, 328–336. https://ajindex.com/articles/297648

References (8)

  1. Kim S, Lwao H. Molecular and cellular mechanisms of angiotensin ll-mediated cardiovascular and renal diseases. pharmacol Rev. 2000; 52:11-34. ACE Inhibitor Myocardial Infarction Collaborative Group, ındications for ACE inhibitors in the early treatment of acute myocardial infarction. Systematic overview of individual data from 100.000 patients in randomized trials. Circulation. 1998; 97:2202-12.
  2. Flather MD, Yusuf S, K0ber L, et al. for the ACE-lnhibitor myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000; 355:1575-81. The Heart outcomes prevention evaluation study investigators. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 32:145-53.
  3. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001; 358:1305-15.
  4. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Nat Cancer Inst. 1959:22:719-48.
  5. Robin JS, Greenland S, Breslow NE. A general estimator of the variance of the Mantel-Haenszel odds ratio. Am J Epidemiol. 1986; 124:719-23.
  6. DerSimonian R, Laird NM. Meta-analysis in clinical trials, controlled Clinical Trials 1986; 7:177-88.
  7. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity arjd combining results from several studies in a meta-analysis. In: Egger M, Davey Smith G, Altman DG. Systematic reviews-in health care: meta-analysis in context. BMJ Publications. 2001. Danish College of General Practitioners. Prevention of ischemic heart disease in clinical practice. Budolfi tryk, Aalborg, Denmark. 1998.
  8. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). New Engl J Med. 1992; 327:678-84. Gruppo Italiano per lo Studio della Sopravvivenza nell'lnfarto Miocardico (GISSIS3) Collaborative Group. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994; 343:1115-22. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. A randomised factorial trial asse